AstraZeneca PLC (AZN.L) LSE

13,214.00

-220(-1.64%)

Updated at June 02 07:14PM

Currency In GBp

Key Executives

Name	Title	Pay	Year Born
Pascal Claude Roland Soriot	Chief Executive Officer & Executive Director	6.12M	1959
Aradhana Sarin	Chief Financial Officer & Executive Director	2.71M	1974
Pam Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board	0	1970
Susan Mary Galbraith	Executive Vice President of Oncology R&D	0	1966
Iskra Reic	Executive Vice President of International	0	N/A
Ruth March	Senior Vice President of Precision Medicine - R&D Oncology	0	N/A
Joris Silon	Head of Investor Relations	0	N/A
David Fredrickson	Executive Vice-President of Oncology Haematology Business Unit	0	1976
Jeffrey Pott	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board	0	N/A
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	0	N/A

Name

Title

Pay

Year Born

Pascal Claude Roland Soriot

Chief Executive Officer & Executive Director

6.12M

1959

Aradhana Sarin

Chief Financial Officer & Executive Director

2.71M

1974

Pam Cheng

EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

1970

Susan Mary Galbraith

Executive Vice President of Oncology R&D

1966

Iskra Reic

Executive Vice President of International

N/A

Ruth March

Senior Vice President of Precision Medicine - R&D Oncology

N/A

Joris Silon

Head of Investor Relations

N/A

David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

1976

Jeffrey Pott

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

N/A

Ruud Dobber

Executive Vice-President of BioPharmaceuticals Business Unit

N/A

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.